Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Romain Ollier

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Characterizing pH-Dependent Interactions Between Immunoglobulin and the Neonatal Fc Receptor Using Surface Plasmon ResonanceSébastien Menant, Damien Nevoltris, Romain Ollier
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Transient Expression and Characterization of Antibodies and Antibody FragmentsGreg Del Val, Florence Gauye, Romain Ollier, et al.
Mabs|January 21, 2020
SPLICELECT™: an adaptable cell surface display technology based on alternative splicing allowing the qualitative and quantitative prediction of secreted product at a single-cell levelChristel Aebischer-Gumy, Pierre Moretti, Romain Ollier, et al.
The Journal of Biological Chemistry|April 29, 2017
Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodiesDarko Skegro, Cian Stutz, Romain Ollier, et al.
Acta Neuropathologica Communications|October 4, 2024
Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTDElodie Chevalier, Mickael Audrain, Monisha Ratnam, et al.
Mabs|August 30, 2019
Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and developmentRomain Ollier, Paul Wassmann, Thierry Monney, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2025
A single dose of a vectorized mAb targeting TDP-43 potently inhibits the neuropathology in a model of ALS/FTDGreg Del Val, Florence Gauye, Mickaël Audrain, et al.
Mabs|July 6, 2023
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human frameworkRomain Ollier, Aline Fuchs, Florence Gauye, et al.
Brain Communications|November 29, 2023
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSFMickael Audrain, Anne-Laure Egesipe, Noémie Tentillier, et al.
Neurobiology of Disease|February 22, 2023
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTDTariq Afroz, Elodie Chevalier, Mickael Audrain, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Characterizing pH-Dependent Interactions Between Immunoglobulin and the Neonatal Fc Receptor Using Surface Plasmon ResonanceSébastien Menant, Damien Nevoltris, Romain Ollier
Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Transient Expression and Characterization of Antibodies and Antibody FragmentsGreg Del Val, Florence Gauye, Romain Ollier, et al.
Mabs|January 21, 2020
SPLICELECT™: an adaptable cell surface display technology based on alternative splicing allowing the qualitative and quantitative prediction of secreted product at a single-cell levelChristel Aebischer-Gumy, Pierre Moretti, Romain Ollier, et al.
The Journal of Biological Chemistry|April 29, 2017
Immunoglobulin domain interface exchange as a platform technology for the generation of Fc heterodimers and bispecific antibodiesDarko Skegro, Cian Stutz, Romain Ollier, et al.
Acta Neuropathologica Communications|October 4, 2024
Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTDElodie Chevalier, Mickael Audrain, Monisha Ratnam, et al.
Mabs|August 30, 2019
Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and developmentRomain Ollier, Paul Wassmann, Thierry Monney, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 16, 2025
A single dose of a vectorized mAb targeting TDP-43 potently inhibits the neuropathology in a model of ALS/FTDGreg Del Val, Florence Gauye, Mickaël Audrain, et al.
Mabs|July 6, 2023
Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human frameworkRomain Ollier, Aline Fuchs, Florence Gauye, et al.
Brain Communications|November 29, 2023
Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSFMickael Audrain, Anne-Laure Egesipe, Noémie Tentillier, et al.
Neurobiology of Disease|February 22, 2023
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTDTariq Afroz, Elodie Chevalier, Mickael Audrain, et al.
Pageof 1